Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Small Cell Lung Carcinoma

ClinicalTrials.gov lists 1,193 trials for Small Cell Lung Carcinoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 59.

MeSH D055752 Neoplasms Neoplasm C04 C08 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 246 Phase 1/2 Phase 1/2 157 Phase 2 Phase 2 409 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 116 Phase 4 Phase 4 12 Not applicable Not applicable 93 Observational Observational 140 Phase 1 Phase 1 246 Phase 1/2 Phase 1/2 157 Phase 2 Phase 2 409 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 116 Phase 4 Phase 4 12 Not applicable Not applicable 93 Observational Observational 140

Trials per phase (log scale)

1 more section with rows

1,193 of the 1,193 trials are tagged with Small Cell Lung Carcinoma itself; the rest are tagged with a narrower condition beneath it.

Get the Small Cell Lung Carcinoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Small Cell Lung Carcinoma trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 93

1991: 1 trials (Phase 2 1) 1993: 3 trials (Phase 2 2, Phase 1 1) 1995: 3 trials (Phase 3 1, Phase 1 2) 1996: 4 trials (Phase 2 2, Phase 1/2 1, Phase 1 1) 1997: 4 trials (Phase 3 1, Phase 2 1, Phase 1 2) 1998: 15 trials (Observational 2, Phase 3 4, Phase 2 5, Phase 1/2 1, Phase 1 3) 1999: 12 trials (Not applicable 2, Phase 3 2, Phase 2 3, Phase 1 5) 2000: 27 trials (Observational 5, Not applicable 1, Phase 3 2, Phase 2 10, Phase 1/2 2, Phase 1 7) 2001: 14 trials (Observational 1, Not applicable 1, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1 5) 2002: 20 trials (Observational 1, Not applicable 1, Phase 3 6, Phase 2/3 1, Phase 2 7, Phase 1 4) 2003: 15 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 4) 2004: 21 trials (Observational 1, Not applicable 1, Phase 2 8, Phase 1/2 1, Phase 1 10) 2005: 19 trials (Observational 3, Not applicable 4, Phase 2 10, Phase 1 2) 2006: 35 trials (Observational 6, Not applicable 5, Phase 4 1, Phase 3 4, Phase 2 16, Phase 1/2 2, Phase 1 1) 2007: 36 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 13, Phase 1/2 5, Phase 1 6) 2008: 30 trials (Observational 6, Not applicable 4, Phase 3 1, Phase 2 13, Phase 1/2 4, Phase 1 2) 2009: 34 trials (Observational 5, Not applicable 3, Phase 3 1, Phase 2/3 1, Phase 2 14, Phase 1/2 2, Phase 1 8) 2010: 26 trials (Observational 6, Not applicable 2, Phase 3 1, Phase 2 7, Phase 1/2 3, Phase 1 7) 2011: 23 trials (Observational 2, Not applicable 3, Phase 3 2, Phase 2 10, Phase 1/2 2, Phase 1 4) 2012: 26 trials (Observational 5, Not applicable 2, Phase 3 2, Phase 2 10, Phase 1/2 4, Phase 1 3) 2013: 28 trials (Observational 1, Not applicable 3, Phase 3 2, Phase 2 11, Phase 1/2 6, Phase 1 5) 2014: 29 trials (Observational 3, Not applicable 7, Phase 2 7, Phase 1/2 7, Phase 1 5) 2015: 28 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 10, Phase 1/2 5, Phase 1 7) 2016: 41 trials (Observational 5, Not applicable 2, Phase 3 3, Phase 2 12, Phase 1/2 6, Phase 1 13) 2017: 57 trials (Observational 6, Phase 3 5, Phase 2/3 2, Phase 2 17, Phase 1/2 13, Phase 1 14) 2018: 53 trials (Observational 2, Not applicable 8, Phase 3 7, Phase 2 20, Phase 1/2 5, Phase 1 11) 2019: 59 trials (Observational 6, Not applicable 4, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 15, Phase 1/2 8, Phase 1 16) 2020: 68 trials (Observational 8, Not applicable 5, Phase 3 5, Phase 2 21, Phase 1/2 14, Phase 1 15) 2021: 72 trials (Observational 7, Not applicable 5, Phase 4 1, Phase 3 8, Phase 2 28, Phase 1/2 12, Phase 1 11) 2022: 49 trials (Observational 8, Not applicable 4, Phase 3 5, Phase 2 23, Phase 1/2 5, Phase 1 4) 2023: 59 trials (Observational 8, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 20, Phase 1/2 10, Phase 1 14) 2024: 79 trials (Observational 11, Not applicable 9, Phase 4 1, Phase 3 11, Phase 2 26, Phase 1/2 6, Phase 1 15) 2025: 93 trials (Observational 14, Not applicable 2, Phase 4 2, Phase 3 13, Phase 2/3 3, Phase 2 28, Phase 1/2 12, Phase 1 19)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 95
2025 93
2024 79
2023 59
2022 49
2021 72
2020 68
2019 59
2018 53
2017 57

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 99 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 215 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 625 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Small Cell Lung Carcinoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 246
Phase 1/2 157
Phase 2 409
Phase 2/3 12
Phase 3 116
Phase 4 12
Not applicable 93
Observational 140
Expanded access 8

How many Small Cell Lung Carcinoma trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 71
Recruiting 215
Enrolling by invitation 7
Active, not recruiting 87
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Small Cell Lung Carcinoma trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 59
AstraZeneca 20
AbbVie 18
Amgen 18
GlaxoSmithKline 15

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Small Cell Lung Carcinoma? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
TOPOTECAN 69
DURVALUMAB 43
Irinotecan 39
PEMBROLIZUMAB 33
(nab)-paclitaxel 29

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Etoposid 116
or carboplatin 103
Cisplatin 1 64
Atezolizumab SC 45
Lurbinectedin alone 25

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Small Cell Lung Carcinoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 808 81
Febrile neutropenia 594 64
Neutrophil count decreased 385 43
Neutropenia 383 44
Anaemia 378 60

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Small Cell Lung Carcinoma? (429)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2026 Yes
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Yes
Population Pharmacokinetics and Exposure-Response Analysis of Serplulimab in Small Cell Lung Cancer Patients. Clinical and translational science 2025 Yes
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2025 Yes
Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer. International journal of biological sciences 2025 Yes

Showing 5 of 429 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (1)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Small cell lung cancer Point prevalence 1-5 / 10 000 Europe Not stated Unspecified

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.

Browse all condition evidence pages